Continuing our series on emerging cancer targets, we are releasing a new free-access database focused on anti-STEAP1 and anti-STEAP2 therapeutic programmes currently in development across preclinical and clinical stages.
👉 Download the free-access database (2026 edition)
STEAP1 (Six-Transmembrane Epithelial Antigen of Prostate 1) and its homolog STEAP2 are cell-surface metalloreductases overexpressed in several solid tumors, with a particularly well-documented expression profile in prostate cancer. Their restricted expression in normal tissues, combined with their accessibility at the plasma membrane, makes them attractive targets for a broad range of therapeutic modalities — from antibody-drug conjugates (ADCs) to T-cell engagers, CAR-T cells, and cancer vaccines.
This 2026 edition compiles publicly disclosed therapeutic programmes targeting STEAP1 and/or STEAP2, with the following highlights:
The database includes programmes from leading pharmaceutical companies, biotechs, and academic centers, including AbbVie, Adcentrx Therapeutics, Amgen, AstraZeneca, Barinthus Biotherapeutics, BioNTech, Genentech, Henlius, Xencor, Xilio Therapeutics, Memorial Sloan Kettering, the University of Pennsylvania, and others.
At Explicyte Immuno-Oncology, we partner with precision oncology teams across the full drug development pipeline:
Missing a programme? Spotted an update? Send it our way and we'll keep the database updated.
👉 Access the anti-STEAP1/2 database
👉 Download the free-access database (2026 edition)
Why STEAP1 and STEAP2?
STEAP1 (Six-Transmembrane Epithelial Antigen of Prostate 1) and its homolog STEAP2 are cell-surface metalloreductases overexpressed in several solid tumors, with a particularly well-documented expression profile in prostate cancer. Their restricted expression in normal tissues, combined with their accessibility at the plasma membrane, makes them attractive targets for a broad range of therapeutic modalities — from antibody-drug conjugates (ADCs) to T-cell engagers, CAR-T cells, and cancer vaccines.
What's inside the database?
This 2026 edition compiles publicly disclosed therapeutic programmes targeting STEAP1 and/or STEAP2, with the following highlights:
- Therapeutic modalities: monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), bispecific and trispecific antibodies, CAR-T cell therapies, and cancer vaccines
- 14 preclinical-stage programmes
- 15 clinical-stage programmes: Phase I/II (14), Phase III (1)
- Cancer indications covered: prostate, lung, gastrointestinal cancers, Ewing sarcoma, and osteosarcoma
The database includes programmes from leading pharmaceutical companies, biotechs, and academic centers, including AbbVie, Adcentrx Therapeutics, Amgen, AstraZeneca, Barinthus Biotherapeutics, BioNTech, Genentech, Henlius, Xencor, Xilio Therapeutics, Memorial Sloan Kettering, the University of Pennsylvania, and others.
How Explicyte supports anti-STEAP programmes
At Explicyte Immuno-Oncology, we partner with precision oncology teams across the full drug development pipeline:
- Target discovery & validation in FFPE tissue samples, leveraging custom FFPE cohorts, single-cell & spatial transcriptomics, and target expression studies by digital pathology
- IO cell-based assays to profile the efficacy and safety of novel modalities — including ADCs, multispecifics, and vaccines
- Clinical trial support through biomarker analysis and early pharmacodynamic signal detection in solid and liquid biopsies
Help us keep the database current
Missing a programme? Spotted an update? Send it our way and we'll keep the database updated.
👉 Access the anti-STEAP1/2 database
